News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
851,152 Results
Type
Article (86741)
Company Profile (703)
Press Release (763706)
Multimedia
Podcasts (139)
Webinars (18)
Section
Business (232776)
Career Advice (4130)
Deals (39749)
Drug Delivery (129)
Drug Development (91062)
Employer Resources (198)
FDA (18158)
Job Trends (17354)
News (396711)
Policy (39798)
Tag
Academia (3002)
Academic (2)
Accelerated approval (9)
Adcomms (32)
Allergies (103)
Alliances (56937)
ALS (112)
Alzheimer's disease (1536)
Antibody-drug conjugate (ADC) (186)
Approvals (18107)
Artificial intelligence (374)
Autoimmune disease (34)
Automation (18)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (124)
Biotechnology (481)
Bladder cancer (95)
Brain cancer (37)
Breast cancer (377)
Cancer (2919)
Cardiovascular disease (235)
Career advice (3537)
Career pathing (34)
CAR-T (200)
CDC (36)
Cell therapy (550)
Cervical cancer (24)
Clinical research (74029)
Collaboration (1045)
Company closure (3)
Compensation (654)
Complete response letters (30)
COVID-19 (2894)
CRISPR (64)
C-suite (319)
Cystic fibrosis (117)
Data (2878)
Decentralized trials (2)
Denatured (48)
Depression (66)
Diabetes (335)
Diagnostics (6962)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (49)
Drug discovery (166)
Drug pricing (148)
Drug shortages (35)
Duchenne muscular dystrophy (125)
Earnings (97418)
Editorial (48)
Employer branding (25)
Employer resources (168)
Events (131259)
Executive appointments (890)
FDA (19765)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (957)
Gene editing (142)
Generative AI (37)
Gene therapy (417)
GLP-1 (899)
Government (5230)
Grass and pollen (6)
Guidances (180)
Healthcare (20911)
Huntington's disease (31)
IgA nephropathy (39)
Immunology and inflammation (171)
Immuno-oncology (8)
Indications (37)
Infectious disease (3070)
Inflammatory bowel disease (163)
Inflation Reduction Act (12)
Influenza (64)
Intellectual property (118)
Interviews (813)
IPO (17888)
IRA (54)
Job creations (5192)
Job search strategy (2861)
Kidney cancer (15)
Labor market (53)
Layoffs (582)
Leadership (25)
Legal (10130)
Liver cancer (84)
Lung cancer (414)
Lymphoma (200)
Machine learning (9)
Management (65)
Manufacturing (413)
MASH (92)
Medical device (14693)
Medtech (14698)
Mergers & acquisitions (22534)
Metabolic disorders (886)
Multiple sclerosis (101)
NASH (23)
Neurodegenerative disease (137)
Neuropsychiatric disorders (39)
Neuroscience (2250)
NextGen: Class of 2025 (7687)
Non-profit (5088)
Now hiring (47)
Obesity (467)
Opinion (286)
Ovarian cancer (96)
Pain (115)
Pancreatic cancer (114)
Parkinson's disease (191)
Partnered (25)
Patents (298)
Patient recruitment (143)
Peanut (54)
People (65605)
Pharmaceutical (143)
Pharmacy benefit managers (24)
Phase I (22859)
Phase II (32148)
Phase III (24199)
Pipeline (1607)
Policy (223)
Postmarket research (3552)
Preclinical (10319)
Press Release (72)
Prostate cancer (138)
Psychedelics (39)
Radiopharmaceuticals (277)
Rare diseases (495)
Real estate (7398)
Recruiting (75)
Regulatory (27011)
Reports (61)
Research institute (2663)
Resumes & cover letters (650)
Rett syndrome (9)
RNA editing (9)
RSV (54)
Schizophrenia (92)
Series A (164)
Series B (108)
Service/supplier (30)
Sickle cell disease (64)
Special edition (22)
Spinal muscular atrophy (167)
Sponsored (36)
Startups (4300)
State (2)
Stomach cancer (16)
Supply chain (80)
Tariffs (63)
The Weekly (89)
Vaccines (880)
Venture capital (52)
Weight loss (317)
Women's health (48)
Worklife (20)
Date
Today (156)
Last 7 days (592)
Last 30 days (2801)
Last 365 days (34283)
2025 (16691)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1272)
Alabama (67)
Alaska (7)
Arizona (279)
Arkansas (14)
Asia (50422)
Australia (8865)
California (7482)
Canada (2307)
China (684)
Colorado (320)
Connecticut (338)
Delaware (192)
Europe (115693)
Florida (1106)
Georgia (255)
Hawaii (1)
Idaho (65)
Illinois (713)
India (32)
Indiana (373)
Iowa (18)
Japan (218)
Kansas (115)
Kentucky (31)
Louisiana (17)
Maine (73)
Maryland (1073)
Massachusetts (5724)
Michigan (269)
Minnesota (468)
Mississippi (3)
Missouri (96)
Montana (32)
Nebraska (26)
Nevada (79)
New Hampshire (73)
New Jersey (2084)
New Mexico (31)
New York (2104)
North Carolina (1212)
North Dakota (10)
Northern California (3223)
Ohio (243)
Oklahoma (16)
Oregon (48)
Pennsylvania (1600)
Puerto Rico (18)
Rhode Island (39)
South America (1653)
South Carolina (34)
South Dakota (1)
Southern California (2758)
Tennessee (123)
Texas (1128)
United States (28283)
Utah (222)
Virginia (201)
Washington D.C. (80)
Washington State (660)
West Virginia (4)
Wisconsin (82)
There are 851,152 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
June 18, 2025
·
5 min read
Obesity
Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped patients lose the same amount of weight as patients on tirzepatide alone while preserving more muscle mass.
June 18, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence
June 18, 2025
·
11 min read
Press Releases
Kye Pharmaceuticals Receives Health Canada Approval for New Dosing Guidance for FIRDAPSE ® and an additional Pediatric Indication
June 18, 2025
·
2 min read
Press Releases
Synfini Inc. and O2nix Bio Announce Strategic Collaboration to Develop Novel Cancer Therapeutics Targeting FTSJ1
June 18, 2025
·
3 min read
Press Releases
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
June 18, 2025
·
1 min read
Press Releases
Neuspera Medical Receives FDA Approval for First Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence
June 18, 2025
·
3 min read
Press Releases
AMGEN’S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
June 18, 2025
·
18 min read
Press Releases
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
June 18, 2025
·
12 min read
Press Releases
ACCC Rural Appalachian Lung Cancer Screening Initiative Fuels Increased, Early Cancer Detection
June 18, 2025
·
2 min read
1 of 85,116
Next
